Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donovan Clark

Psychiatry Danville, VA Medical Doctor

NPI 1235199100 CMS profile 426908

382 Taylor Dr, Danville, VA 24541

Open in the dashboard

General payments

$14,457

697 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donovan Clark of Danville, VA is reported in the CMS Open Payments database as having received $14,457 across 697 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,747 121
2024 General $3,605 155
2023 General $3,188 130
2022 General $1,897 101
2021 General $1,439 79
2020 General $446 24
2019 General $1,135 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donovan Clark
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Donovan Clark were reported at $2,747. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Donovan Clark Psychiatry median Middle half National median
2019 $1,135 $184 $59–$605 $163
2020 $446 $119 $36–$372 $114
2021 $1,439 $143 $43–$576 $132
2022 $1,897 $153 $50–$590 $149
2023 $3,188 $170 $56–$651 $160
2024 $3,605 $179 $57–$673 $164
2025 $2,747 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $2,094 78 payments
  2. Otsuka America Pharmaceutical, Inc. $2,033 106 payments
  3. Alkermes, Inc. $1,882 103 payments
  4. Janssen Pharmaceuticals, Inc $1,759 68 payments
  5. AbbVie, Inc. $1,270 79 payments
  6. Vanda Pharmaceuticals Inc. $1,268 51 payments
  7. Teva Pharmaceuticals USA, Inc. $946 52 payments
  8. Neurocrine Biosciences, Inc. $928 39 payments
  9. Lundbeck LLC $779 47 payments
  10. E.R. Squibb & Sons, L.L.C. $431 23 payments
  11. Other $1,066 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,423 695 payments
  2. Education $34 2 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $1,795 99 payments
  2. ARISTADA Cns $1,795 99 payments
  3. INVEGA SUSTENNA $1,707 65 payments
  4. CAPLYTA $1,654 64 payments
  5. LYBALVI $1,560 73 payments
  6. ARISTADA Cns $1,502 82 payments
  7. ARISTADA Cns $1,502 82 payments
  8. ABILIFY MAINTENA $1,311 73 payments
  9. FANAPT $1,244 50 payments
  10. VRAYLAR $1,091 67 payments
  11. Other $8,194 418 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

697 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record